Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage
Department of Quantitative Health Sciences
Adult; Age Factors; Anti-HIV Agents; California; Cohort Studies; Databases, Factual; Female; HIV Infections; Humans; Intracranial Hemorrhages; Male; Medicaid; Middle Aged; Pyridines; Pyrones; Risk Factors; United States; Veterans
Immune System Diseases | Investigative Techniques | Medical Pharmacology
The US Food and Drug Administration has issued a warning that tipranavir may be associated with increased risk of intracranial hemorrhage. We studied 2 large cohorts to estimate the background rate of intracranial hemorrhage and compared it with rates reported among persons who had been exposed to tipranavir.
DOI of Published Version
Clin Infect Dis. 2008 Nov 1;47(9):1226-30. doi: 10.1086/592302. Link to article on publisher's site
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Justice, Amy C.; Zingmond, David S.; Gordon, Kirsha S.; Fultz, Shawn L.; Goulet, Joseph L.; King, Joseph T. Jr.; Bravata, Dawn M.; Valdez, Hernan; Kraft, Michael; and Mattocks, Kristin M., "Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage" (2008). Women’s Health Research Faculty Publications. 577.